ArticleThrombosis journal2025
Enhanced platelets aggregation and coagulation of methicillin-resistant Staphylococcus aureus compared to methicillin-sensitive Staphylococcus aureus.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionStaphylococcus aureus (S. aureus) is well known for its ability to activate platelets and to induce plasma coagulation through different pathways. GAP STATEMENT: Enhanced human platelet aggregation and plasma coagulation by methicillin-resistant S. aureus (MRSA) have not been reported.
aimThis study aims to investigate platelets and coagulation activities of MRSA strains compared to methicillin-sensitive strains of S. aureus (MSSA).
methodsWell-characterized bacterial strains of Coagulase-negative Staphylococci (CoNS) (n = 25), and Coagulase-positive Staphylococci (CoPS) including MRSA (n = 25) and MSSA (n = 25) using phenotype and genotype analysis were compared for their coagulation and aggregation abilities. Isolates were tested for slide and tube coagulase test, mixed with human plasma and investigated for coagulation ability using manual and automated prothrombin time (PT), partial thromboplastin time (PTT), clotting time (CT), and thrombin time (TT) or mixed with human platelet rich plasma (PRP) and analyzed for reduced platelets count (aggregation) and for platelets aggregations using chrono-log aggregometer.
resultsMRSA isolates have faster, and stronger tube coagulase test compared to MSSA isolates. MRSA isolates compared to MSSA isolates have significantly reduced manual PT (7.2 ± 1.2 s vs. 10.5 ± 2 s, P < 0.0001), significantly reduced PTT (16.1 ± 1.5 s vs. 23.8 ± 2 s, P < 0.0001), and significantly reduced CT (84 ± 117.2 min vs. 148.3 ± 195 min, P < 0.0001). Similarly, MRSA isolates have significantly reduced PT, PTT, and TT compared to MSSA (P < 0.0001) using an automated coagulation analyzer. MRSA isolates induce a significant decrease in platelet count compared to MSSA (90.3 ± 35.9 vs. 121.1 ± 42.6, P < 0.001). MRSA isolates have significantly increased PRP aggregation compared to MSSA isolates indicated by increased aggregation maximum amplitude, aggregation slope, and area under the curve (P < 0.0001). PT test distinguishes CoPS from CoNS with 100% sensitivity and 98% specificity.
conclusionsEnhanced plasma coagulation and platelet aggregation of MRSA compared to MSSA strains is another virulence factor that increases MRSA protection, decreases antibiotics diffusion, and leads to thrombotic/clotting complications. PT is a useful diagnostic test for distinguishing CoPS from CoNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.